The loop takes agentic AI a step further by authorizing a swarm of agents to work continuously in the background, endlessly.

The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...

The number of American men in the workforce are at its lowest level in two decades — with about one in three American men having stopped working as of 2026, new labor statistics show. Just 66% of men ...

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

Richard Socher's new $650 million startup wants to build an AI that can research and improve itself indefinitely — and he insists it will actually ship products.

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is among the must-buy penny stocks to invest in now. Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is accelerating its drug development programs and unlocking ...

If you’re applying for jobs, you better get used to being interviewed by AI. Here’s how to ace an interview. Photo: Johnny Simon/WSJ, iStock For employees at a Dell Technologies office, mornings used ...

ARLINGTON, Texas — Before the drivers start their engines, hundreds of IndyCar crew members are fast at work with the Grand Prix of Arlington ready to debut this weekend. “This one seems like it’s ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. You might not be destined for a cubicle after all. As a number of big-name companies increase their ...

SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

The consensus mark for RXRX's Q4 loss and sales are pinned at 28 cents per share and $25.5M, respectively. In late 2025, RXRX highlighted REC-4881 data showing rapid, durable polyp reductions in FAP ...